124 citations
,
January 2012 in “Journal of Allergy and Clinical Immunology” This study found that activation of cannabinoid 1 receptors in human scalp hair follicles may limit excessive mast cell activation and maturation, suggesting a potential therapeutic strategy for managing MC-dependent skin diseases.
75 citations
,
August 2018 in “Biochemical pharmacology” This review discusses the potential of targeting the endocannabinoid system for treating skin disorders and reports no new clinical results, highlighting the need for further research.
18 citations
,
February 2020 in “Journal of pharmaceutical and biomedical analysis” This study using high-performance liquid chromatography reported that mice with more diverse gut microbiota had higher levels of specific compounds in hair compared to those with less diversity, with stress affecting certain plasma levels.
11 citations
,
October 2020 in “General and comparative endocrinology” This study found that age-related fluctuations in hormones and endocannabinoids in male C57BL/6 mice showed specific patterns, with peak values observed around 2.7 to 3.4 months, with these patterns seen in both plasma and hair but with different magnitudes.
2 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” This study found that Hataedock may alleviate atopic dermatitis symptoms in mice by maintaining skin homeostasis and improving skin barrier formation through the endocannabinoid system.
June 2026 in “CUNY Academic Works (City University of New York)” This study developed and validated a method for measuring stress biomarkers in hair during pregnancy, finding that glucocorticoid levels increased over trimesters while endocannabinoid levels remained constant, suggesting hair analysis as a reliable tool for monitoring stress responses in pregnant women.
August 2016 in “Journal of Investigative Dermatology” This study suggests that enhancing endocannabinoid tone with an EMT-inhibitor may have anti-inflammatory effects and slightly increase sebaceous lipid production, which could be beneficial for dry skin conditions.
5 citations
,
January 2020 in “Research journal of pharmacy and technology” This review explores the potential benefits of non-psychoactive Cannabidiol for reducing stress and pain associated with Polycystic Ovarian Syndrome and reports no new clinical findings.
January 2015 in “Elsevier eBooks” This study suggests that targeting the endocannabinoid system through pharmacological interventions may help reduce compulsive hair-pulling in individuals with trichotillomania.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” In this study, OEA was found to significantly enhance sebaceous lipogenesis and potentially reduce inflammation in human sebocytes, suggesting it as a promising candidate for treating skin dryness.
98 citations
,
July 2014 in “Trends in Molecular Medicine” This article discusses the role of human hair follicles in neuroendocrinology and suggests potential new therapeutic targets by examining how neuromediators influence hair growth, pigmentation, and stem cell biology in organ cultures.
58 citations
,
March 2011 in “Pflügers Archiv für die gesamte Physiologie des Menschen und der Tiere/Pflügers Archiv” Hormones and signaling pathways control sebaceous gland function and could help treat acne.
28 citations
,
January 2017 in “EBioMedicine” This study discusses potential anti-inflammatory roles of endocannabinoid system modulation and phytocannabinoids in skin health, but reports no new clinical results; the authors emphasize the need for further clinical exploration.
21 citations
,
November 2022 in “Frontiers in immunology” This article reviews sebaceous immunobiology and highlights the complex role of sebaceous glands and sebocytes in skin barrier function and inflammation, particularly in acne pathogenesis, but reports no new results.
20 citations
,
August 2021 in “Journal of Cosmetic Dermatology” This review examines the potential use and challenges of topical cannabinoids for skin diseases and hair growth, highlighting limited clinical data on their efficacy and safety.
14 citations
,
February 2021 in “Experimental Dermatology” This study found that activating CB1 receptor signaling in human hair follicles increased stem cell proliferation while reducing differentiated cell survival, suggesting CB1's role as a survival stimulus for epithelial stem cells.
9 citations
,
April 2025 in “Psychoneuroendocrinology” This study found no consistent differences between the posterior vertex and occipital region for hair hormone analysis, but noted significant variations in specific hormone concentrations, highlighting the need for standardized sampling practices.
3 citations
,
December 2022 in “Cells” This review examines the role of cannabinoid compounds in treating various skin conditions and suggests their potential as systemic and topical therapies, but it reports no new experimental results.
1 citations
,
March 2023 in “Portuguese Journal of Dermatology and Venereology” This case report describes a 15-year-old girl with alopecia universalis who experienced scalp hair regrowth after self-medicating with cannabis, suggesting it may have potential as a treatment for autoimmune diseases like alopecia areata.
April 2023 in “Journal of Investigative Dermatology” In this study, a new emulsion containing CBD and ginger root extract significantly reduced symptoms of dry and eczema-prone skin, such as erythema and itching, in a clinical trial.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that in an ex vivo setting, 17β-estradiol increased CB1 expression in human hair follicles, suggesting possible sensitivity to endocannabinoids and a potential mechanism for hair therapy.
January 2017 in “Springer eBooks” The document concludes that scalp health is influenced by complex factors affecting sebaceous glands, including hormones, aging, and various substances.
January 2022 in “Clinical dermatology open access journal” This review summarizes research on cannabinoids like CBD and THCV, reporting that they improve hair growth in patients with androgenetic alopecia when applied topically, with CBD showing a dose-dependent effect.
September 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study introduces the MHS Hair Restoration Protocol, a systems-biology model targeting hair follicle health through the gut-microbiome-endocannabinoidome axis and innovative topical treatments, emphasizing a holistic approach to pattern hair loss.
September 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This research introduces the MHS Hair Restoration Protocol, which is a comprehensive approach aimed at restoring the hair follicle environment by modulating the gut-microbiome-endocannabinoidome axis and incorporating specific dietary and topical strategies, rather than focusing only on short-term hair count improvements.
July 2024 in “Medical alphabet” In this review, researchers discuss the factors contributing to early graying, such as genetic predisposition, oxidative stress imbalance, and nutrient deficiencies, and highlight potential restoration methods involving palmitoyl tetrapeptide-20 and the endocannabinoid system in hair follicles.
In this study, marijuana use and depression were associated with a higher likelihood of being treated for lower urinary tract symptoms in men over 45 in a marijuana-legalized region.
14 citations
,
March 2016 in “Cutaneous and Ocular Toxicology” This study observed that SC users commonly exhibited dermatological findings like periorbital darkening and blade scars, highlighting the importance for dermatologists to recognize these markers for early diagnosis and intervention.
142 citations
,
March 2019 in “Molecules/Molecules online/Molecules annual” This review discusses the role of the endocannabinoid system in skin health and disease, highlighting its potential for future research and applications, but reports no new experimental results.
50 citations
,
May 2019 in “Drugs” This review discusses the potential therapeutic effects of targeting the endocannabinoid system for chemotherapy-induced peripheral neuropathy and reports no new clinical results, highlighting the need for ongoing research.